WebJun 4, 2024 · A single dose of Bezlotoxumab (Zinplava) 10mg/kg (actual body weight) 60-minute intravenous infusion during active CDI treatments. Other Name: No intervention. No Intervention: Historical control. Cohort of historical patients matched to study population to serve as control. WebOct 22, 2016 · were reported in 29% of ZINPLAVA-treated patients and 33% of placebo-treated patients. Heart failure was reported as a serious adverse reaction in 2.3% of ZINPLAVA-treated patients and 1.0% of placebo-treated patients. In ZINPLAVA-treated patients, 10% experienced one or more infusion specific adverse reactions compared to …
Zinplava Prices, Coupons & Patient Assistance Programs
WebDec 26, 2024 · Bezlotoxumab (Zinplava) is a human monoclonal antibody that was approved by the United States Food and Drug Administration (FDA) in October 2016 as adjunctive therapy for the management of patients at high risk for recurrent CDI. ... To determine the cost-effectiveness of bezlotoxumab compared with placebo, Prabhu et al … WebMar 13, 2024 · Merck Access Program for Zinplava This program provides brand name medications at no or low cost: Provided by: Merck Patient Assistance Program, Inc. Merck Access Program PO Box 29067 Phoenix, AZ 85038. TEL: 877-709-4455 FAX: 800-977-1957: Languages Spoken: English, Others By Translation Service does pitt have a good medical school
Zinplava (bezlotoxumab): Basics, Side Effects & Reviews - GoodRx
WebZinplava (bezlotoxumab) is a member of the immune globulins drug class and is commonly used for Prevention of Recurrent Clostridioides difficile Infection. The cost for Zinplava intravenous solution (25 mg/mL) is around $4,011 for a supply of 40 milliliters, depending … WebEven if the medication is working, you may experience some unwanted side effects. Contact your doctor immediately if you experience any of the following: Heart failure: shortness of breath, wheezing, swelling, tired, confusion, faster heart rate. The following side effects may get better over time as your body gets used to the medication. WebSep 9, 2024 · Background Clostridioides difficile infection (CDI) is one of the leading nosocomial infections, resulting in increased hospital length of stay and additional treatment costs. Bezlotoxumab, the first monoclonal antibody against CDI, has an 1 A guideline recommendation for prevention of CDI, after randomized clinical trials demonstrated its … facebook san felipe mmm